Shu-Hong Zhu, Ph.D. is a Professor of Family Medicine and Public Health and the Director of the Center for Research and Intervention in Tobacco Control (CRITC) at the University of California, San Diego. His tobacco control research focuses on two tracks: treatment research for individual smokers and population analysis of large datasets. He has been the Principal Investigator for the California Smokers’ Helpline since its inception in 1992. The Helpline is internationally recognized for its scientific innovation and its dedication to the dissemination of research findings to public health services. His recent work focuses on the interface of individual- and population-based approaches to smoking cessation and the effects of social norms on smoking behavior. He examines how population-level tobacco use patterns change in response to public health policy or to social norms. This also includes examination of the impact of emerging tobacco products on population-level tobacco use patterns and the market-driven influence on health behavior. Dr. Zhu has received many awards, including the California Wellness Foundation/ University of California Wellness Lecture Award and the APHA Excellence Award from the American Public Health Association.
-
- Explain two ways that the 211 population is a good target for smoking cessation intervention efforts.
- Describe three results of an outreach effort to smokers through 211 in California
- Compare two results of 211 outreach with that of EMR referrals
CME/CE credit is available for the recorded version of this live activity. Scroll down the page and click on the "Get Credit" button to begin.
Certificates of Attendance
Click here to generate a certificate of attendance for participating on this webinar.
Disclosures
This UCSF CME activity was planned and developed to uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.
All speakers, planning committee members and reviewers have disclosed they have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Catherine Bonniot, Anita Browning, Christine Cheng, Brian Clark, Jennifer Matekuare, Ma Krisanta Pamatmat, MPH, CHES, Jessica Safier, MA, Maya Vijayaraghavan, MD, MAS, and Shu-Hong Zhu, PhD.